This study evaluated the effect of angiotensin (Ang)-(1–7) on vascular remodelling in a rat autologous jugular vein graft model in which rats underwent autologous jugular vein graft transplantation (Ang-[1–7] and control groups) or sham surgery (sham group). The animals received continuous jugular infusion of Ang-(1–7) at 25 μg/kg per h (Ang-[1–7] group) or normal saline (control and sham groups) starting 3 days after surgery. Ang-(1–7) infusion reduced venous graft hyperplasia, vascular remodelling, extracellular signal-regulated kinase 1/2 (ERK1/2) activation, p38 mitogen-activated protein kinase (MAPK) activation and levels of proliferating cell nuclear antigen and α-smooth muscle actin compared with control animals. The vascular tissue Ang II level was higher in Ang-(1–7) and control rats than in sham animals. These findings suggest that Ang-(1–7) acts by inhibiting the activation of ERK1/2 and p38 MAPK in vascular tissue. The use of exogenous Ang-(1–7) could improve the outcome of vein grafting through the attenuation of vascular remodelling.
AllaireEClowesAW: Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg1997; 63: 582–591.
2.
ChauxARuanXMFishbeinMC: Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg1998; 115: 604–614.
3.
FerreiraAJSantosRAS: Cardiovascular actions of angiotensin-(1–7). Braz J Med Biol Res2005; 38: 499–507.
4.
WangHQBaiLShenBR: Coculture with endothelial cells enhances vascular smooth muscle cell adhesion and spreading via activation of β1-integrin and phosphatidylinositol 3-kinase/Akt. Eur J Cell Biol2007; 86: 51–62.
5.
FreemanEJChisolmGMFerrarioCM: Calmodulin-dependent protein phosphatase: immunocytochemical localization in chick retina. Hypertension1996; 28: 104–108.
6.
GallagherPETallantEA: Inhibition of human lung cancer cell growth by angiotensin-(1–7). Carcinogenesis2004; 25: 2045–2052.
7.
YuPJFerrariGPirelliL: Vascular injury and modulation of MAPKs: A targeted approach to therapy of restenosis. Cell Signal2007; 19: 1359–1371.
8.
JeremyJYDashwoodMRTimmM: Nitric oxide synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein grafts. Ann Thorac Surg1997; 63: 470–476.
9.
WallittEJevonMHornickPI: Therapeutics of vein graft intimal hyperplasia: 100 years on. Ann Thorac Surg2007; 84: 317–323.
10.
KoyamaHOlsonNEDastvanFF: Cell replication in the arterial wall: activation of signalling pathway following in vivo injury. Circ Res1998; 82: 713–721.
11.
KucharewiczIPawlakRMatysT: Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1–7). Hypertension2002; 40: 774–779.
12.
LangeveldBvan GilstWHTioRA: Angiotensin-(1–7) attenuates neointimal formation after stent implantation in the rat. Hypertension2005; 45: 138–141.
13.
LiuBFisherMGrovesP: Down-regulation of the ERK1 and ERK2 mitogen-activated protein kinases using antisense oligonucleotides inhibits intimal hyperplasia in a porcine model of coronary balloon angioplasty. Cardiovasc Res2002; 54: 640–648.
14.
MatsumotoTKomoriKYonemitsuY: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg1998; 27: 135–144.
15.
PawasheABGolinoPAmbrosioG: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res1994; 74: 56–63.
16.
KucharewiczIChabielskaEPawlakD: The antithrombotic effect of angiotensin-(1–7) closely resembles that of losartan. J Renin Angiotensin Aldosterone Syst2000; 1: 268–272.
17.
NakashimaHSuzukiHOhtsuH: Angiotensin II regulates vascular and endothelial dysfunction: recent topics of angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol2006; 4: 67–78.
O'BrienJEJrShiYFardA: Wound healing around and within saphenous vein bypass grafts. J Thorac Cardiovasc Surg1997; 114: 38–45.
20.
American Society of Mammalogists: Guidelines for the capture, handling, and care of mammals as approved by the American Society of Mammalogists. J Mammal198879: 1416–1431.
LeaskRLButanyJJohnstonKW: Human saphenous vein coronary artery bypass graft morphology, geometry and hemodynamics. Ann Biomed Eng2005; 33: 301–309.
23.
GrondinCMMeereCCastonguayY: Progressive and late obstruction of an aortocoronary venous bypass graft. Circulation1971; 43: 698–702.
24.
PintucciGFroumSPinnellJ: Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost2002; 88: 834–842.
25.
RenYGarvinJLCarreteroOA: Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension2002; 39: 799–802.
26.
SampaioWOde CastroC HenriqueSantosRA: Angiotensin-(1–7) counter-regulates angiotensin II signaling in human endothelial cells. Hypertension2007; 50: 1093–1098.
27.
TallantEAClarkMA: Molecular mechanisms of inhibition of vascular growth by angiotensin-(1–7). Hypertension2003; 42: 574–579.
28.
SantosRACampagnole-SantosMJAndradeSP: Angiotensin-(1–7): an update. Regul Pept2000; 91: 54–62.
29.
ShuhaiberJHEvansANMassadMG: Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg2002; 22: 387–396.
30.
WangXTournierC: Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal2006; 18: 753–760.
31.
SaundersPCPintucciGBizekisCS: Vein graft arterialization causes differential activation of mitogen-activated protein kinases. J Thorac Cardiovasc Surg2004; 127: 1276–1284.
32.
VerdecchiaPAngeliFMazzottaG: The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag2008; 4: 971–981.
33.
NieWYanHLiS: Angiotensin-(1–7) enhances angiotensin II-induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol Immunol2009; 46: 355–361.
34.
GianiJFMuñozMCMayerMA: Angiotensin-(1–7) improves cardiac remodeling and inhibits growth promoting pathways in the heart of fructose-fed rats. Am J Physiol Heart Circ Physiol2010; 298: H1003–H1013.
